A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer

NCT04750382 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-negative Breast Cancer

Interventions

DRUG: HX008+Cisplatin+Gemcitabine

Sponsor

Taizhou Hanzhong biomedical co. LTD